Contact Lenses - Medical Devices Market Parameters Pipeline Assessment Review, 2016

Summary

GlobalData's Medical Devices sector report, “Contact Lenses - Medical Devices Pipeline Assessment, 2016" provides an overview of Contact Lenses currently in pipeline stage.The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Complete report details @ https://www.wiseguyreports.com/reports/417086/contact-lenses-medical-devices-pipeline-assessment-2016

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Contact Lenses under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Contact Lenses under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Request a sample report @ https://www.wiseguyreports.com/sample_request/417086/contact-lenses-medical-devices-pipeline-assessment-2016

Table of Contents

1 Table of Contents 2

    1.1 List of Tables 6

    1.2 List of Figures 10

2 Introduction 11

    2.1 Contact Lenses Overview 11

3 Products under Development 12

    3.1 Contact Lenses - Pipeline Products by Stage of Development 12

    3.2 Contact Lenses - Pipeline Products by Segment 13

    3.3 Contact Lenses - Pipeline Products by Territory 14

    3.4 Contact Lenses - Pipeline Products by Regulatory Path 15

    3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 16

    3.6 Contact Lenses - Ongoing Clinical Trials 17

4 Contact Lenses - Pipeline Products under Development by Companies 18

    4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 18

    4.2 Contact Lenses - Pipeline Products by Stage of Development 20

5 Contact Lenses Companies and Product Overview 23

    5.1 Aeon Astron Corporation Company Overview 23

      5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23

    5.2 Alcon, Inc. Company Overview 24

      5.2.1 Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24

    5.3 Apeliotus Ophthalmics Company Overview 29

      5.3.1 Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview 29

    5.4 Auburn University Company Overview 31

      5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 31

    5.5 Axcelon Biopolymers Corp. Company Overview 33

      5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 33

    5.6 Bausch & Lomb Incorporated Company Overview 34

      5.6.1 Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview 34

    5.7 Body Organ Biomedical Corp. Company Overview 38

      5.7.1 Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview 38

    5.8 Children's Hospital Boston Company Overview 40

      5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 40

    5.9 CooperVision, Inc. Company Overview 42

      5.9.1 CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview 42

    5.10 EP Global Communications, Inc. Company Overview 43

      5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43

    5.11 Euclid Systems Corporation Company Overview 44

      5.11.1 Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview 44

    5.12 Eyenovations Company Overview 45

      5.12.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 45

    5.13 EyeYon Medical Company Overview 46

      5.13.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 46

    5.14 Imperial College London Company Overview 49

      5.14.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 49

    5.15 Johnson & Johnson Vision Care, Inc. Company Overview 50

      5.15.1 Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

    5.16 Massachusetts Eye and Ear Infirmary Company Overview 54

      5.16.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 54

    5.17 Novartis AG Company Overview 56

      5.17.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 56

    5.18 Ocular Dynamics, LLC Company Overview 57

      5.18.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 57

    5.19 Ocutec Limited Company Overview 58

      5.19.1 Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview 58

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/417086/contact-lenses-medical-devices-pipeline-assessment-2016

    5.20 Presbia Plc Company Overview 59

      5.20.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 59

    5.21 Stanford University Company Overview 62

      5.21.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 62

    5.22 The Hong Kong University of Science and Technology Company Overview 63

      5.22.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 63

    5.23 The University of New South Wales Company Overview 64

      5.23.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 64

    5.24 UltraVision CLPL Company Overview 65

      5.24.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 65

    5.25 University of California, San Diego Company Overview 66

      5.25.1 University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview 66

    5.26 University of Florida Company Overview 68

      5.26.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 68

    5.27 University of Valencia Company Overview 69

      5.27.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 69

    5.28 University of Washington Company Overview 71

      5.28.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 71

    5.29 University of Western Ontario Company Overview 74

      5.29.1 University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview 74

    5.30 Valeant Pharmaceuticals International, Inc. Company Overview 75

      5.30.1 Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75

    5.31 Visioneering Technologies, Inc. Company Overview 95

      5.31.1 Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95

    5.32 VISTAKON Pharmaceuticals, LLC Company Overview 101

      5.32.1 VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview 101

    5.33 Yolia Health Company Overview 102

      5.33.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 102

6 Contact Lenses- Recent Developments 103

    6.1 Mar 03, 2016: The Cooper Companies Announces First Quarter 2016 Results 103

    6.2 Mar 01, 2016: First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits 104

    6.3 Feb 19, 2016: Strong growth in revenue and earnings Essilor focused on its 2018 objectives 104

    6.4 Feb 12, 2016: Carl Zeiss Meditec Grows, Boosted by Currency Tailwinds / Strongest Growth Once Again in Surgical Ophthalmology 105

    6.5 Feb 05, 2016: Briefing Summary of the Analyst/Investor Meeting for the 3rd Quarter Financial Results for the Fiscal Year Ending March 31, 2016 Tokyo, January 29, 2016 106

    6.6 Jan 29, 2016: Hoya Reports Third Quarter Results; Record Nine Months Results 109

    6.7 Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 110

    6.8 Jan 15, 2016: HOYA Presents Hoya EyeGenius 119

 Check Discount on this report @ https://www.wiseguyreports.com/check_discount/417086/contact-lenses-medical-devices-pipeline-assessment-2016

   6.9 Dec 16, 2015: AEA Investors to Acquire Majority Stake in 1-800 Contacts from Thomas H. Lee Partners 120

    6.10 Dec 16, 2015: Carl Zeiss Meditec increases revenue to € 1,040 million / Market shares expanded in a number of markets 120

    6.11 Dec 03, 2015: The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results 121

    6.12 Nov 10, 2015: Bausch + Lomb Announces 2016 Launch of Bausch + Lomb ULTRA Contact Lenses for Presbyopia 122

    6.13 Nov 09, 2015: Unicon Optical to Acquire Taiwan-Based Contact Lenses Company 123

    6.14 Nov 06, 2015: Shanghai Conant Optics Plans to Raise up to USD188.6 Million in Private Placement of Shares 123

    6.15 Oct 27, 2015: Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance 123

    6.16 Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 130

    6.17 Oct 12, 2015: EPGL to Grant CooperVision Exclusive Licenses in Exchange for Royalties and Compensation Agreement by November 6, 2015 131

    6.18 Oct 08, 2015: Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation 131

    6.19 Oct 05, 2015: Presbia Introduces Time-Saving Disposable Microlens Inserter 132

    6.20 Sep 17, 2015: Presbia Flexivue Microlens Implanted in More Than 1,000 Patients Worldwide 132

    6.21 Sep 17, 2015: QSpex Technologies Enters into Agreement with Shanghai Conant Optical 132

    6.22 Sep 14, 2015: HOYA Vision Care Establishes Subsidiary in Turkey 133

    6.23 Sep 10, 2015: Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 133

    6.24 Sep 10, 2015: Johnson & Johnson Vison Care Launches New Lens With A Tear-Infused Design 133

    6.25 Sep 03, 2015: Presbia to Complete Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens 134

    6.26 Sep 03, 2015: The Cooper Companies Announces Third Quarter 2015 Results 135

    6.27 Aug 24, 2015: Results of Patient Outcomes Outside of the U.S. Demonstrate Safety and Effectiveness of Presbia Flexivue Mircolens 136

    6.28 Aug 10, 2015: Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment 136

    6.29 Aug 05, 2015: Essilor International Raises USD328.4 Million in Public Offering of Notes Due 2017 137

    6.30 Aug 03, 2015: Xavier Galliot, Chief Sustainability Officer of the Essilor Group 137

    6.31 Jul 30, 2015: Essilor of America to Acquire Vision Source from Brazos Private Equity 137

    6.32 Jul 30, 2015: Essilor Announces Strong results ; A winning strategy 137

    6.33 Jul 29, 2015: Hoya Announces First Quarter Results Ended June 30, 2015 138

    6.34 Jul 29, 2015: Hoya Reports First Quarter Financial Results 140

    6.35 Jul 28, 2015: Valeant Pharmaceuticals Presented with Economic Development Support from Rochester Gas & Electric for the Bausch + Lomb ULTRA Contact Lens Manufacturing Line Expansion in Rochester, NY 141

    6.36 Jul 21, 2015: Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches 141

    6.37 Jul 13, 2015: Valeant Pharma to Acquire Unilens Vision 149

    6.38 Jul 09, 2015: Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study 149

    6.39 Jun 23, 2015: Bausch + Lomb’s Biotrue ONEday for Presbyopia Contact Lenses Now Available in Expanded High Add Powers 149

    6.40 Jun 22, 2015: Visioneering Technologies Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue Lenses 150

    6.41 Jun 04, 2015: The Cooper Companies Announces Second Quarter 2015 Results 150

    6.42 Jun 01, 2015: NVISION Eye Centers Performs First KAMRA Inlay in California 151

    6.43 May 15, 2015: Ultravision Expands Licensing Agreement with Art Optical 152

    6.44 May 14, 2015: Unilens Vision Reports Third Quarter Operating Results 152

    6.45 May 12, 2015: Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit 154

    6.46 May 04, 2015: NVISION Eye Centers Becomes One of the First in the U.S. to Offer Breakthrough KAMRA Inlay for Near Vision Loss Associated With Aging 155

    6.47 May 03, 2015: Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO 155

    6.48 Apr 23, 2015: Novartis delivered sales growth, significant margin expansion and strong innovation in Q1; now with a more focused portfolio 156

    6.49 Apr 21, 2015: Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens in Australia 163

    6.50 Apr 21, 2015: Revenue up very sharply by 25.4% Annual targets confirmed 163

    6.51 Apr 18, 2015: Durrie Vision First in Region to Provide Corneal Implant Designed to Treat Presbyopia 165

    6.52 Apr 18, 2015: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges 165

    6.53 Apr 17, 2015: FDA approves first-of-its-kind corneal implant to improve near vision in certain patients 167

    6.54 Apr 16, 2015: Visioneering Technologies Introduces NaturalVue 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision 168

7 Appendix 169

    7.1 Methodology 169

    7.2 About GlobalData 171

    7.3 Contact Us 172

    7.4 Disclaimer 172

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=417086

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)